ArticleVaccine2018
Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.
Article in Vaccine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Human Organoids as a Novel Tool for Vaccine Study.Advanced healthcare materials · 2026Review
- Escherichia coli in the production of biopharmaceuticals.Biotechnology and applied biochemistry · 2025Review
- Recombinant production platform for Group A Streptococcus glycoconjugate vaccines.NPJ vaccines · 2025Article
- Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae.PloS one · 2025Article
- Engineering Escherichia coli for increased Und-P availability leads to material improvements in glycan expression technology.Microbial cell factories · 2024Article
- Recent advances in the biosynthesis of polysaccharide-based antimicrobial glycoconjugate vaccines.Frontiers in microbiology · 2024Review
- In silico design of an epitope-based vaccine against PspC in Streptococcus pneumoniae using reverse vaccinology.Journal, genetic engineering & biotechnology · 2023Article
- Development of a novel glycoengineering platform for the rapid production of conjugate vaccines.Microbial cell factories · 2023Article
- Preparation of a Klebsiella pneumoniae conjugate nanovaccine using glycol-engineered Escherichia coli.Microbial cell factories · 2023Article
- 30-Minute Highly Multiplexed VaxArray Immunoassay for Pneumococcal Vaccine Antigen Characterization.Vaccines · 2022Article
- Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines.Microbial cell factories · 2022Article
- Production of Vaccines Using Biological Conjugation.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Bacteria-Based Microdevices for the Oral Delivery of Macromolecules.Pharmaceutics · 2021Review
- Development of an automated platform for the optimal production of glycoconjugate vaccines expressed in Escherichia coli.Microbial cell factories · 2021Article
- A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.Research square · 2021Article
- Article
- "A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques."bioRxiv : the preprint server for biology · 2020Article
- Synthetic Glycobiology: Parts, Systems, and Applications.ACS synthetic biology · 2020Review
- Application of anMicroorganisms · 2020Article
- Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy.Molecular and cellular probes · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Streptococcus pneumoniae is the leading cause of bacterial pneumonia. Although this is a vaccine preventable disease, S. pneumoniae still causes over 1 million deaths per year, mainly in children under the age of five. The biggest disease burden is in the developing world, which is mainly due to unavailability of vaccines due to their high costs. Protein polysaccharide conjugate vaccines are given routinely in the developed world to children to induce a protective antibody response against S. pneumoniae. One of these vaccines is Prevnar13, which targets 13 of the 95 known capsular types. Current vaccine production requires growth of large amounts of the 13 serotypes, and isolation of the capsular polysaccharide that is then chemically coupled to a protein, such as the diphtheria toxoid CRM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.